The core of data analysis tools lies in transforming complex data into understandable information. Its main characteristics ...

Dianthus Therapeutics announces positive Phase II results for Claseprubart in myasthenia gravis, highlighting best-in-class potential.

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered ...

New complementary technologies will also be featured, including SpeedAkin ™ Anatomic Compression Implant used in Akin osteotomy procedures, as well biologics commonly used in foot and ankle fusion ...

ESCCA As a leading forum for scientific exchange in flow cytometry, ESCCA focuses on clinical applications in hematology, immunology, cancer, and cell biology. ESCCA 2025 will be held in Montpellier, ...

An announcement from The Arena Group ( ($AREN) ) is now available. On September 11, 2025, The Arena Group Holdings, Inc. released an updated ...

Merck (MRK) stock in focus as the company posts late-stage trial data to indicate that its Capvaxive pneumonia vaccine is ...

CuFe Limited ( ($AU:CUF) ) has provided an announcement. CuFe Limited has updated its Corporate Presentation to meet ASX Listing Rules ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual ...

Compared to placebo, sotagliflozin reduced the rate of the primary endpoint (total CV death and hospitalization or urgent visit for HF) overall (8.5 vs 11.8 events/100 person-years [p-y]; hazard ratio ...